Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENVARSUS XR vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Prophylaxis of organ rejection in kidney transplant patients,Prophylaxis of organ rejection in liver transplant patients
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal half-life approximately 25-30 hours in stable renal transplant patients. Longer half-life (up to 50 hours) in patients with hepatic impairment.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily hepatic via CYP3A4 and CYP3A5; also metabolized by intestinal CYP3A4.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily fecal (94%) with minor renal excretion (2.2% as unchanged drug). Biliary excretion is a significant route.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 99% bound to erythrocytes and plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.9-1.4 L/kg in renal transplant patients; large volume indicates extensive tissue distribution, particularly to red blood cells.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral bioavailability is approximately 15-25% with the extended-release formulation; reduced by high-fat meal, so should be taken consistently on an empty stomach.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
No specific GFR-based dose adjustment; however, due to nephrotoxicity, monitor renal function closely and reduce dose if renal impairment occurs. For patients with severe renal impairment (Cr Cl <30 m L/min), consider alternative immunosuppression.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
In patients with mild to moderate hepatic impairment (Child-Pugh A or B), reduce dose by 25%. For severe hepatic impairment (Child-Pugh C), reduce dose by 50% and monitor trough levels closely.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
For pediatric kidney transplant recipients: 0.2 mg/kg/day orally once daily, with morning meal. Adjust to target trough concentrations. Safety and efficacy not established for other indications in pediatrics.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment; however, elderly patients may have increased susceptibility to nephrotoxicity and neurotoxicity. Use lowest effective dose, monitor renal function, and adjust based on trough levels.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Increased susceptibility to infection and possible development of malignancy (e.g., lymphoma, skin cancer).
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Nephrotoxicity, neurotoxicity, hypertension, hyperkalemia, post-transplant diabetes mellitus, monitoring of blood concentrations required.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to tacrolimus or any component of the formulation.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Grapefruit and grapefruit juice increase tacrolimus exposure and must be avoided. High-fat meals may decrease absorption; consistency of food intake relative to dosing is recommended. Alcohol should be limited due to potential additive hepatotoxicity.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on animal studies; human data are limited but suggest a possible small increase. During the second and third trimesters, risks include intrauterine growth restriction, preterm delivery, and transient neonatal hyperkalemia and renal dysfunction. Advise women of childbearing potential to use effective contraception.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Tacrolimus is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.5 (range 0.12–0.75). Infant exposure is estimated to be <1% of the maternal weight-adjusted dose, which is considered low. However, due to potential for immunosuppression and adverse effects, breastfeeding is generally not recommended unless benefits outweigh risks. Monitor infant for signs of immunosuppression.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Pregnancy induces pharmacokinetic changes including increased volume of distribution, altered protein binding, and enhanced clearance of tacrolimus. Frequent monitoring of trough concentrations is essential to maintain therapeutic levels (target 5–10 ng/m L). Dose adjustments (increases of 20–50% or more) are often required, especially during the second and third trimesters. Postpartum, doses should be reduced to pre-pregnancy levels within 1–2 weeks.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
ENVARSUS XR is an extended-release formulation of tacrolimus; conversion from immediate-release tacrolimus requires close therapeutic drug monitoring due to altered pharmacokinetics. Administer consistently with or without food to minimize variability. Avoid grapefruit products. Monitor renal function, blood pressure, electrolytes, glucose, and trough tacrolimus levels. CYP3A4/5 inducers/inhibitors significantly affect tacrolimus exposure; adjust dose accordingly. Do not crush, chew, or split tablets.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take exactly as prescribed, at the same time each day, with or without food but consistently.,Swallow whole; do not crush, chew, or break the tablet.,Avoid grapefruit and grapefruit juice.,Do not stop or change dose without consulting your doctor.,Report signs of infection (fever, sore throat), tremor, headache, changes in urination, or unusual bleeding.,Avoid live vaccines and limit sun exposure due to increased skin cancer risk.,Keep all appointments for blood tests to monitor drug levels and organ function.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENVARSUS XR vs ALFENTA, answered by our medical review team.
ENVARSUS XR is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENVARSUS XR and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENVARSUS XR is: 0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENVARSUS XR and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENVARSUS XR is classified as Category C. Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on anima. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.